Unknown PHASE2 INTERVENTIONAL 1-arm NCT03219762

Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC (Nabster)

Phase II Study of Nab-paclitaxel in Sensitive and Refractory Relapsed Small Cell Lung Cancer (Nabster Study)

Sponsor: Clirest s.r.l.

Updated 8 times since 2017 Last updated: Jul 24, 2017 Started: Feb 7, 2017 Primary completion: Jan 31, 2019 Completion: Jan 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Small Cell Lung Cancer and is currently ongoing. Clirest s.r.l. leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Aug 2019 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 3 earlier versions

Nov 2018 — Aug 2019 [monthly]

Recruiting PHASE2
Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE2
Aug 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Feb 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clirest s.r.l.
Gruppo Oncologico Italiano di Ricerca Clinica
Istituto Toscano Tumori
Mipharm S.p.A.
Temas srl

Data source: Gruppo Oncologico Italiano di Ricerca Clinica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Bergamo, Italy , Bologna, Italy , Bolzano, Italy , Brindisi, Italy , Carpi, Italy , Cona, Italy , Cremona, Italy , Cuneo, Italy , Florence, Italy and 15 more locations